Genetic Interpretation of the Impacts of Honokiol and EGCG on Apoptotic and Self-Renewal Pathways in HEp-2 Human Laryngeal CD44^high Cancer Stem Cells

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Timmermans AJ, de Gooijer CJ, Hamming–Vrieze O, Hilgers FJ, van den Brekel MW. T3-T4 laryngeal cancer in The Netherlands Cancer Institute; 10-year results of the consistent application of an organ-preserving/-sacrificing protocol. Head Neck. 2015;37(10):1495–1503. doi:10.1002/hed.23789
   PubMed Web of Science ®Google Scholar
• Finlan L, Hupp T. Epidermal stem cells and cancer stem cells: insights into cancer and potential therapeutic strategies. Eur J Cancer. 2006;42(9):1283–1292. doi:10.1016/j.ejca.2006.01.047
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111. doi:10.1038/35102167
   PubMed Web of Science ®Google Scholar
• Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138(5):822–829. doi:10.1016/j.cell.2009.08.017
   PubMed Web of Science ®Google Scholar
• Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer. 2013;49(15):3210–3218. doi:10.1016/j.ejca.2013.06.025
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807–1821. doi:10.1016/j.bcp.2011.07.093
   PubMed Web of Science ®Google Scholar
• Lee J-H, Jeong Y-J, Lee S-W, Kim D, Oh S-J, Lim H-S, Oh H-K, Kim S-H, Kim W-J, Jung J-Y, et al. EGCG induces apoptosis in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria with the release of apoptosis-inducing factor and endonuclease G. Cancer Lett. 2010;290(1):68–75. doi:10.1016/j.canlet.2009.08.027
   PubMed Web of Science ®Google Scholar
• Wang X, Hao M-W, Dong K, Lin F, Ren J-H, Zhang H-Z. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res. 2009;32(9):1263–1269. doi:10.1007/s12272-009-1912-8
   PubMed Web of Science ®Google Scholar
• Shin YS, Kang SU, Park JK, Kim YE, Kim YS, Baek SJ, Lee S-H, Kim C-H. Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of β-catenin. Phytomedicine. 2016;23(12):1344–1355. doi:10.1016/j.phymed.2016.07.005
   PubMed Web of Science ®Google Scholar
• Liu L, Hou L, Gu S, Zuo X, Meng D, Luo M, Zhang X, Huang S, Zhao X. Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2015;33(1):297–303. doi:10.3892/or.2014.3555
   PubMed Web of Science ®Google Scholar
• Efferth T. Stem cells, cancer stem-like cells, and natural products. Planta Med. 2012;78(10):935–942. doi:10.1055/s-0031-1298540
   PubMed Web of Science ®Google Scholar
• Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3–NFκB signaling. Anticancer Res. 2015;35(1):39–46.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Chao L-K, Hung P-H, Chen Y-J. EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation. Int J Clin Exp Pathol. 2014;7(5):2372–2381.
   PubMed Web of Science ®Google Scholar
• Kumazoe M, Takai M, Hiroi S, Takeuchi C, Yamanouchi M, Nojiri T, Onda H, Bae J, Huang Y, Takamatsu K, et al. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep. 2017;7(1):1917. doi:10.1038/s41598-017-02162-9
   PubMed Web of Science ®Google Scholar
• Toden S, Tran H-M, Tovar-Camargo OA, Okugawa Y, Goel A. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016;7(13):16158–16171. doi:10.18632/oncotarget.7567
   PubMedGoogle Scholar
• Tang S-N, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 2010;5:14. doi:10.1186/1750-2187-5-14
   PubMedGoogle Scholar
• Zhu J, Jiang Y, Yang X, Wang S, Xie C, Li X, Li Y, Chen Y, Wang X, Meng Y, et al. Wnt/β-catenin pathway mediates (-)-epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem cells. Biochem Biophys Res Commun. 2017;482(1):15–21. doi:10.1016/j.bbrc.2016.11.038
   PubMed Web of Science ®Google Scholar
• Tang S-N, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. 2012;131(1):30–40. doi:10.1002/ijc.26323
   PubMed Web of Science ®Google Scholar
• Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009;11(5):1139–1148. doi:10.1089/ars.2009.2440
   PubMed Web of Science ®Google Scholar
• Hahm E-R, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther. 2007;6(10):2686–2695. doi:10.1158/1535-7163.MCT-07-0217
   PubMed Web of Science ®Google Scholar
• Hua H, Chen W, Shen L, Sheng Q, Teng L. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45(9):773–779. doi:10.1093/abbs/gmt071
   PubMed Web of Science ®Google Scholar
• Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz C-O, Elstner E, Possinger K, Eucker J, et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol. 2008;591(1-3):43–51. doi:10.1016/j.ejphar.2008.06.026
   PubMed Web of Science ®Google Scholar
• Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 2006;4(9):621–633. doi:10.1158/1541-7786.MCR-06-0076
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005;106(5):1794–1800. doi:10.1182/blood-2005-01-0346
   PubMed Web of Science ®Google Scholar
• Chen X-R, Lu R, Dan H-X, Liao G, Zhou M, Li X-Y, Ji N. Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells. Int J Oral Sci. 2011;3(1):34–42. doi:10.4248/IJOS11014
   PubMed Web of Science ®Google Scholar
• Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010;16(9):2571–2579. doi:10.1158/1078-0432.CCR-10-0333
   PubMed Web of Science ®Google Scholar
• Singh T, Gupta NA, Xu S, Prasad R, Velu SE, Katiyar SK. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor. Oncotarget. 2015;6(25):21268–21282. doi:10.18632/oncotarget.4178
   PubMedGoogle Scholar
• Kim D-W, Ko SM, Jeon Y-J, Noh Y-W, Choi N-J, Cho S-D, Moon HS, Cho YS, Shin J-C, Park S-M, et al. Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. Int J Oncol. 2013;43(4):1103–1110. doi:10.3892/ijo.2013.2028
   PubMed Web of Science ®Google Scholar
• Huang J-S, Yao C-J, Chuang S-E, Yeh C-T, Lee L-M, Chen R-M, Chao W-J, Whang-Peng J, Lai G-M. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer. 2016;16:245. doi:10.1186/s12885-016-2265-6
   PubMed Web of Science ®Google Scholar
• Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, et al. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. Oncogene. 2017;36(41):5709–5721. doi:10.1038/onc.2017.164
   PubMed Web of Science ®Google Scholar
• Yao C-J, Lai G-M, Yeh C-T, Lai M-T, Shih P-H, Chao W-J, Whang-Peng J, Chuang S-E, Lai T-Y. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/β-catenin signaling and apoptosis induction. Evid Based Complement Alternat Med. 2013;2013:146136.
   PubMed Web of Science ®Google Scholar
• Lai I-C, Shih P-H, Yao C-J, Yeh C-T, Wang-Peng J, Lui T-N, Chuang S-E, Hu T-S, Lai T-Y, Lai G-M, et al. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells. PloS One. 2015;10(3):e0114830. doi:10.1371/journal.pone.0114830
   PubMed Web of Science ®Google Scholar
• Ponnurangam S, Mammen JMV, Ramalingam S, He Z, Zhang Y, Umar S, Subramaniam D, Anant S. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol Cancer Ther. 2012;11(4):963–972. doi:10.1158/1535-7163.MCT-11-0999
   PubMed Web of Science ®Google Scholar
• Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, Fu R, Liu Q, Wen S, Wang B, et al. Identification and characterization of CD133 + CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer. 2017;8(3):497–506. doi:10.7150/jca.17444
   PubMed Web of Science ®Google Scholar
• Guzel E, Karatas O, Ozgurses M, Ozen M. New insights into laryngeal squamous cell carcinoma: cancer stem-like cells. Cancer Res Front. 2015;1(2):138–148. doi:10.17980/2015.138
   Google Scholar
• Wei X, Wang J, He J, Ma B, Chen J. Biological characteristics of CD133+ cancer stem cells derived from human laryngeal carcinoma cell line. Int J Clin Exp Med. 2014;7(9):2453–2462.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou L, Dou T, Wan G, Tang H, Tian J. BMI1’S maintenance of the proliferative capacity of laryngeal cancer stem cells. Head Neck. 2011;33(8):1115–1125. doi:10.1002/hed.21576
   PubMed Web of Science ®Google Scholar
• Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PloS One. 2013;8(12):e83971. doi:10.1371/journal.pone.0083971
   PubMed Web of Science ®Google Scholar
• Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T, Nakamura S, Niwa S, Ikeda S, Koga H, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 2010;285(6):4060–4073. doi:10.1074/jbc.M109.056523
   PubMed Web of Science ®Google Scholar
• Wang X, Liu M, Zhao C. Expression of ezrin and moesin related to invasion, metastasis and prognosis of laryngeal squamous cell carcinoma. Genet Mol Res. 2014;13(3):8002–8013. doi:10.4238/2014.September.29.13
   PubMed Web of Science ®Google Scholar
• Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–R615. doi:10.1186/bcr920
   PubMed Web of Science ®Google Scholar
• Dai M-Y, Fang F, Zou Y, Yi X, Ding Y-J, Chen C, Tao Z-Z, Chen S-M. Downregulation of Notch1 induces apoptosis and inhibits cell proliferation and metastasis in laryngeal squamous cell carcinoma. Oncol Rep. 2015;34(6):3111–3119. doi:10.3892/or.2015.4274
   PubMed Web of Science ®Google Scholar
• Lee SH, Do SI, Lee HJ, Kang HJ, Koo BS, Lim YC. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab Invest. 2016;96(5):508–516. doi:10.1038/labinvest.2015.163
   PubMed Web of Science ®Google Scholar
• Atlasi Y, Looijenga L, Fodde R. Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. Curr Top Dev Biol. 2014; 107: 373–404. doi:10.1016/B978-0-12-416022-4.00013-5
   Google Scholar
• Lee SH, Koo BS, Kim JM, Huang S, Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH, Lim YC, et al. Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4. J Pathol. 2014;234(1):99–107. doi:10.1002/path.4383
   PubMed Web of Science ®Google Scholar
• Rohatgi R, Scott MP. Patching the gaps in Hedgehog signalling. Nat Cell Biol. 2007;9(9):1005–1009. doi:10.1038/ncb435
   PubMed Web of Science ®Google Scholar
• Dimitrova K, Stoehr M, Dehghani F, Dietz A, Wichmann G, Bertolini J, Mozet C. Overexpression of the Hedgehog signalling pathway in head and neck squamous cell carcinoma. Onkologie. 2013;36(5):279–286. doi:10.1159/000350322
   PubMedGoogle Scholar
• Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–464. doi:10.1038/nrclinonc.2015.61
   PubMed Web of Science ®Google Scholar
• Etienne-Selloum N, Dandache I, Sharif T, Auger C, Schini-Kerth VB. Polyphenolic compounds targeting p53-family tumor suppressors: current progress and challenges. In Y. Cheng (Ed.), Future aspects of tumor suppressor gene. 2013; 129–67. InTech. doi:10.5772/56471
   Google Scholar
• Min NY, Kim J-H, Choi J-H, Liang W, Ko YJ, Rhee S, Bang H, Ham SW, Park AJ, Lee K-H, et al. Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochem Biophys Res Commun. 2012;421(1):91–7. doi:10.1016/j.bbrc.2012.03.120
   PubMed Web of Science ®Google Scholar
• Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer. 2005;114(4):513–521. doi:10.1002/ijc.20785
   PubMed Web of Science ®Google Scholar
• Singh T, Prasad R, Katiyar SK. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics. 2013;8(1):54–65. doi:10.4161/epi.23078
   PubMed Web of Science ®Google Scholar
• Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276(16):13322–13330. doi:10.1074/jbc.M004209200
   PubMed Web of Science ®Google Scholar
• Lin D, Yan Z, Chen A, Ye J, Hu A, Liu J, Peng J, Wu X. Anti-proliferative activity and structure-activity relationship of honokiol derivatives. Bioorg Med Chem. 2019;27(16):3729–3734. doi:10.1016/j.bmc.2019.06.042
   PubMed Web of Science ®Google Scholar
• Lin JM, Gowda AP, Sharma AK, Amin S. In vitro growth inhibition of human cancer cells by novel honokiol analogs. Bioorg Med Chem. 2012;20(10):3202–3211. doi:10.1016/j.bmc.2012.03.062
   PubMed Web of Science ®Google Scholar
• Orrenius S, Nicotera P, Zhivotovsky B. Cell death mechanisms and their implications in toxicology. Toxicol Sci. 2011;119(1):3–19. doi:10.1093/toxsci/kfq268
   PubMed Web of Science ®Google Scholar
• Tian W, Xu D, Han W, He H, Cai H, Chen H, Zhou M, Chen J, Deng Y-C. Cyclophilin D modulates cell death transition from early apoptosis to programmed necrosis induced by honokiol. Int J Oncol. 2013;42(5):1654–1663. doi:10.3892/ijo.2013.1863
   PubMed Web of Science ®Google Scholar
• Bleau A-M, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226–235. doi:10.1016/j.stem.2009.01.007
   PubMed Web of Science ®Google Scholar
• Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, Mantilla A, Pickard RS, Robson CN, Heer R, et al. Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. PloS One. 2012;7(11):e50690. doi:10.1371/journal.pone.0050690
   PubMed Web of Science ®Google Scholar
• Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA. 2007;104(41):16158–16163. doi:10.1073/pnas.0702596104
   PubMed Web of Science ®Google Scholar
• Chen X, Li Y, Lin Q, Wang Y, Sun H, Wang J, Cui G, Cai L, Dong X. Tea polyphenols induced apoptosis of breast cancer cells by suppressing the expression of Survivin. Sci Rep. 2014;4:4416. doi:10.1038/srep04416
   PubMed Web of Science ®Google Scholar
• Tian W, Deng Y, Li L, He H, Sun J, Xu D. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic ed necrotic death. Int J Oncol. 2013;42(2):721–732. doi:10.3892/ijo.2012.1739
   PubMed Web of Science ®Google Scholar
• Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10(24):4256–4271. doi:10.4161/cc.10.24.18552
   PubMed Web of Science ®Google Scholar
• Avtanski DB, Nagalingam A, Kuppusamy P, Bonner MY, Arbiser JL, Saxena NK, Sharma D. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner. Oncotarget. 2015;6(18):16396–16410. doi:10.18632/oncotarget.3844
   PubMedGoogle Scholar
• Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–658. doi:10.1016/j.cell.2009.02.038
   PubMed Web of Science ®Google Scholar
• Sánchez‐Peris M, Murga J, Falomir E, Carda M, Marco JA. Synthesis of honokiol analogues and evaluation of their modulating action on VEGF protein secretion and telomerase-related gene expressions. Chem Biol Drug Des. 2017;89(4):577–584. doi:10.1111/cbdd.12880
   PubMed Web of Science ®Google Scholar
• Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2001;7(12):4220–4229.
   PubMed Web of Science ®Google Scholar
• Gao S-Y, Li E-M, Cui L, Lu X-F, Meng L-Y, Yuan H-M, Xie J-J, Du Z-P, Pang J-X, Xu L-Y, et al. Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem. 2009;284(12):7995–8004. doi:10.1074/jbc.M809734200
   PubMed Web of Science ®Google Scholar
• Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B, Li L, et al. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci. 2015;106(6):700–708. doi:10.1111/cas.12656
   PubMed Web of Science ®Google Scholar
• Averett C, Bhardwaj A, Arora S, Srivastava SK, Khan MA, Ahmad A, Singh S, Carter JE, Khushman M, Singh AP, et al. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. Carcinogenesis. 2016;37(11):1052–1061. doi:10.1093/carcin/bgw096
   PubMed Web of Science ®Google Scholar
• Singh AP, Arora S, Bhardwaj A, Srivastava SK, Kadakia MP, Wang B, Grizzle WE, Owen LB, Singh S. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions. J Biol Chem. 2012;287(46):39115–39124. doi:10.1074/jbc.M112.409581
   PubMed Web of Science ®Google Scholar
• Lin W, Tongyi S. Role of Bax/Bcl-2 family members in green tea polyphenol induced necroptosis of p53-deficient Hep3B cells. Tumour Biol. 2014;35(8):8065–8075. doi:10.1007/s13277-014-2064-0
   PubMedGoogle Scholar
• Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006;108(8):2804–2810. doi:10.1182/blood-2006-05-022814
   PubMed Web of Science ®Google Scholar
• Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012;149(7):1536–1548. doi:10.1016/j.cell.2012.05.014
   PubMed Web of Science ®Google Scholar